Aligos Therapeutics Inc (ALGS)
0.7887
-0.03
(-3.58%)
USD |
NASDAQ |
Apr 26, 16:00
0.7887
0.00 (0.00%)
After-Hours: 20:00
Aligos Therapeutics Research and Development Expense (Quarterly): 22.26M for Dec. 31, 2023
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 22.26M |
| September 30, 2023 | 15.87M |
| June 30, 2023 | 16.78M |
| March 31, 2023 | 18.14M |
| December 31, 2022 | 19.10M |
| September 30, 2022 | 17.79M |
| June 30, 2022 | 16.51M |
| March 31, 2022 | 31.68M |
| December 31, 2021 | 28.60M |
| Date | Value |
|---|---|
| September 30, 2021 | 28.13M |
| June 30, 2021 | 24.55M |
| March 31, 2021 | 22.87M |
| December 31, 2020 | 28.08M |
| September 30, 2020 | 17.33M |
| June 30, 2020 | 17.18M |
| March 31, 2020 | 17.30M |
| December 31, 2019 | 14.97M |
| September 30, 2019 | 11.73M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
11.73M
Minimum
Sep 2019
31.68M
Maximum
Mar 2022
20.49M
Average
17.96M
Median
Research and Development Expense (Quarterly) Benchmarks
| Mirum Pharmaceuticals Inc | 30.94M |
| CEL-SCI Corp | 4.352M |
| AIM ImmunoTech Inc | 3.20M |
| IGC Pharma Inc | 0.903M |
| NovaBay Pharmaceuticals Inc | 0.004M |